Benefit of Targretin® Capsules in NSCLC
Note: results supported by additional clinical studies in lung and kidney cancer patients
Targretin® Survival Capsules(1) ECOG
- Estimated Median Survival: 14 Months 8 Months
- Patients at MTD alive > 2 years: 32% 12%(2)
- Estimated One-Year Survival: 61% 33%
- Estimated Three-Year Survival: 19% %
(1) At Maximum Tolerated Dose (2) Projected 2-year survival Data published in May 15, 2001, issue of The Journal of Clinical Oncology